CSL reported a challenging first half for FY 2026, with revenue declining 4% and a significant drop in net profit after tax, reflecting one-off costs and government policy impacts, but remains committed to a robust transformation strategy.

• Revenue fell 4% on a constant currency basis, with NPATA down 7%.
• Net profit after tax plummeted 81% due to one-off transformation costs and asset impairments.
• Strong operational cash flow of $1.3 billion; share buyback program expanded from $500 million to $750 million.
• Strategic transformation initiatives are progressing well, targeting simplified operations and enhanced growth.
• Guidance for the full year remains unchanged, with optimism for recovery driven by Ig, albumin, and new product launches.